Education
About Us
Working with TipRanks
Follow Us
Bioventix PLC (GB:BVXP)
LSE:BVXP
BVXP Stock Chart & Stats
1800.00p
56.00p(1.70%)
At close: 4:00 PM EST
1800.00p
56.00p(1.70%)
Day’s Range― - ―
52-Week Range1,550.00p - 3,020.00p
Previous CloseN/A
Volume24.00
Average Volume (3M)7.85K
Market Cap
£84.90M
Enterprise Value75.91M
Total Cash (Recent Filing)£5.08M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)11.2
Beta0.46
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.33%
Share Statistics
EPS (TTM)0.72
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.93
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.36
Revenue Forecast (FY)£12.50M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetZero reported debt and an equity-funded structure provide durable financial flexibility. For a small, specialized reagents supplier this reduces refinancing risk, supports steady dividend policy, and allows management to fund selective R&D or support customers through product lifecycle disruptions without leverage strain.
Elite Profitability And MarginsVery high gross and net margins reflect a differentiated IP-led product set and low variable costs, producing persistent earnings power. High margins support strong internal cash generation, fund dividends and reinvestment, and create a wide buffer versus cyclical revenue swings common in diagnostics markets.
Durable Royalties From Design-insThe business model of design-in antibodies creates long-lived royalties and recurring reagent sales because assays remain certified in labs for years. High switching costs and regulatory validation requirements give installed placements durable revenue visibility and scalable upside as test volumes grow over multi-year horizons.
Bears Say
Recent Revenue & FCF SlowdownA decline in revenue and free cash flow in 2025 interrupts prior growth momentum and reduces near-term cash earmarked for dividends, R&D, or stock retention. If prolonged it can erode reinvestment capacity and limit ability to secure new design-ins or scale manufacturing to meet future demand.
Market Pressure In ChinaReported headwinds in China point to structural market-access and demand risks in a key diagnostics geography. Persistent regulatory, competitive, or volume pressure there would constrain long-term growth of royalty streams and make future assay rollouts and customer negotiations more difficult.
Customer/design-in Concentration RiskRevenue depends on a small number of successful design-ins with large diagnostic OEMs. Loss or non-renewal of a major placement, or unfavorable renegotiation with a dominant customer, could materially reduce recurring royalties and reagent sales given limited product breadth and a small employee base to rapidly diversify.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1550.00p and its highest was 3020.00p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £84.90M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Mar 30, 2026 which is in 30 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Oct 27, 2025. The company reported 0.72p earnings per share for the quarter, missing the consensus estimate of 0.78p by -0.06p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 80p which represents an annual dividend yield of 8.33%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.72p in its last earnings report, missing expectations of 0.78p. Following the earnings report the stock price went down -15.699%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth £53.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
64.40%
Trailing 12-Months
Asset Growth
-1.05%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---